Wall Street brokerages expect Insulet Co. (NASDAQ:PODD) to post $125.25 million in sales for the current quarter, according to Zacks Investment Research. Ten analysts have made estimates for Insulet’s earnings. The highest sales estimate is $127.49 million and the lowest is $124.20 million. Insulet reported sales of $103.58 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 20.9%. The firm is scheduled to announce its next earnings report after the market closes on Wednesday, February 21st.
According to Zacks, analysts expect that Insulet will report full-year sales of $125.25 million for the current year, with estimates ranging from $457.40 million to $460.79 million. For the next financial year, analysts forecast that the company will report sales of $556.15 million per share, with estimates ranging from $510.43 million to $588.51 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Insulet.
Insulet (NASDAQ:PODD) last released its quarterly earnings data on Thursday, November 2nd. The medical instruments supplier reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.06. The firm had revenue of $121.80 million for the quarter, compared to analysts’ expectations of $114.02 million. Insulet had a negative net margin of 6.66% and a negative return on equity of 43.85%. The company’s revenue for the quarter was up 28.4% compared to the same quarter last year. During the same quarter last year, the business posted ($0.05) earnings per share.
In other news, Director James C. Mullen bought 2,500 shares of the stock in a transaction that occurred on Monday, November 13th. The stock was bought at an average cost of $67.45 per share, for a total transaction of $168,625.00. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 2.60% of the company’s stock.
Hedge funds have recently bought and sold shares of the stock. Capital Research Global Investors increased its position in Insulet by 2.5% during the second quarter. Capital Research Global Investors now owns 5,883,633 shares of the medical instruments supplier’s stock worth $301,889,000 after buying an additional 145,724 shares during the period. Vanguard Group Inc. raised its position in shares of Insulet by 2.2% during the 2nd quarter. Vanguard Group Inc. now owns 4,655,119 shares of the medical instruments supplier’s stock worth $238,854,000 after purchasing an additional 98,272 shares during the period. Frontier Capital Management Co. LLC raised its position in shares of Insulet by 42.4% during the 4th quarter. Frontier Capital Management Co. LLC now owns 2,096,131 shares of the medical instruments supplier’s stock worth $144,633,000 after purchasing an additional 624,465 shares during the period. Fred Alger Management Inc. increased its position in Insulet by 4.2% in the 2nd quarter. Fred Alger Management Inc. now owns 1,264,025 shares of the medical instruments supplier’s stock valued at $64,857,000 after acquiring an additional 50,780 shares during the period. Finally, State Street Corp increased its position in Insulet by 7.7% in the 2nd quarter. State Street Corp now owns 1,189,155 shares of the medical instruments supplier’s stock valued at $61,014,000 after acquiring an additional 85,280 shares during the period.
Insulet (NASDAQ:PODD) traded up $0.02 during trading on Friday, hitting $78.08. 122,017 shares of the stock traded hands, compared to its average volume of 560,357. The company has a market capitalization of $4,524.68, a PE ratio of -156.16 and a beta of 1.58. The company has a debt-to-equity ratio of 4.65, a quick ratio of 4.42 and a current ratio of 4.88. Insulet has a 52-week low of $38.43 and a 52-week high of $78.65.
Insulet Company Profile
Insulet Corporation is engaged in the development, manufacturing and sale of the Omnipod Insulin Management System (the Omnipod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.